Persons ‘never treated’ in mass drug administration for lymphatic filariasis: identifying programmatic and research needs from a series of research review meetings 2020–2021
As neglected tropical disease programs rely on participation in rounds of mass drug administration (MDA), there is concern that individuals who have never been treated could contribute to ongoing transmission, posing a barrier to elimination. Previous research has suggested that the size and charact...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Oxford University Press
2023
|
| _version_ | 1811141141835284480 |
|---|---|
| author | Brady, MA Toubali, E Baker, M Long, E Worrell, C Ramaiah, K Graves, P Hollingsworth, TD Kelly-Hope, L Stukel, D Tripathi, B Means, AR Matendechero, SH Krentel, A |
| author_facet | Brady, MA Toubali, E Baker, M Long, E Worrell, C Ramaiah, K Graves, P Hollingsworth, TD Kelly-Hope, L Stukel, D Tripathi, B Means, AR Matendechero, SH Krentel, A |
| author_sort | Brady, MA |
| collection | OXFORD |
| description | As neglected tropical disease programs rely on participation in rounds of mass drug administration (MDA), there is concern that individuals who have never been treated could contribute to ongoing transmission, posing a barrier to elimination. Previous research has suggested that the size and characteristics of the never-treated population may be important but have not been sufficiently explored. To address this critical knowledge gap, four meetings were held from December 2020 to May 2021 to compile expert knowledge on never treatment in lymphatic filariasis (LF) MDA programs. The meetings explored four questions: the number and proportion of people never treated, their sociodemographic characteristics, their infection status and the reasons why they were not treated. Meeting discussions noted key issues requiring further exploration, including how to standardize measurement of the never treated, adapt and use existing tools to capture never-treated data and ensure representation of never-treated people in data collection. Recognizing that patterns of never treatment are situation specific, participants noted measurement should be quick, inexpensive and focused on local solutions. Furthermore, programs should use existing data to generate mathematical models to understand what levels of never treatment may compromise LF elimination goals or trigger programmatic action. |
| first_indexed | 2024-09-25T04:33:10Z |
| format | Journal article |
| id | oxford-uuid:3c8288ed-5b2f-40f2-b334-898cf8e8ef25 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-09-25T04:33:10Z |
| publishDate | 2023 |
| publisher | Oxford University Press |
| record_format | dspace |
| spelling | oxford-uuid:3c8288ed-5b2f-40f2-b334-898cf8e8ef252024-09-05T20:09:37ZPersons ‘never treated’ in mass drug administration for lymphatic filariasis: identifying programmatic and research needs from a series of research review meetings 2020–2021Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:3c8288ed-5b2f-40f2-b334-898cf8e8ef25EnglishJisc Publications RouterOxford University Press2023Brady, MAToubali, EBaker, MLong, EWorrell, CRamaiah, KGraves, PHollingsworth, TDKelly-Hope, LStukel, DTripathi, BMeans, ARMatendechero, SHKrentel, AAs neglected tropical disease programs rely on participation in rounds of mass drug administration (MDA), there is concern that individuals who have never been treated could contribute to ongoing transmission, posing a barrier to elimination. Previous research has suggested that the size and characteristics of the never-treated population may be important but have not been sufficiently explored. To address this critical knowledge gap, four meetings were held from December 2020 to May 2021 to compile expert knowledge on never treatment in lymphatic filariasis (LF) MDA programs. The meetings explored four questions: the number and proportion of people never treated, their sociodemographic characteristics, their infection status and the reasons why they were not treated. Meeting discussions noted key issues requiring further exploration, including how to standardize measurement of the never treated, adapt and use existing tools to capture never-treated data and ensure representation of never-treated people in data collection. Recognizing that patterns of never treatment are situation specific, participants noted measurement should be quick, inexpensive and focused on local solutions. Furthermore, programs should use existing data to generate mathematical models to understand what levels of never treatment may compromise LF elimination goals or trigger programmatic action. |
| spellingShingle | Brady, MA Toubali, E Baker, M Long, E Worrell, C Ramaiah, K Graves, P Hollingsworth, TD Kelly-Hope, L Stukel, D Tripathi, B Means, AR Matendechero, SH Krentel, A Persons ‘never treated’ in mass drug administration for lymphatic filariasis: identifying programmatic and research needs from a series of research review meetings 2020–2021 |
| title | Persons ‘never treated’ in mass drug administration for lymphatic filariasis: identifying programmatic and research needs from a series of research review meetings 2020–2021 |
| title_full | Persons ‘never treated’ in mass drug administration for lymphatic filariasis: identifying programmatic and research needs from a series of research review meetings 2020–2021 |
| title_fullStr | Persons ‘never treated’ in mass drug administration for lymphatic filariasis: identifying programmatic and research needs from a series of research review meetings 2020–2021 |
| title_full_unstemmed | Persons ‘never treated’ in mass drug administration for lymphatic filariasis: identifying programmatic and research needs from a series of research review meetings 2020–2021 |
| title_short | Persons ‘never treated’ in mass drug administration for lymphatic filariasis: identifying programmatic and research needs from a series of research review meetings 2020–2021 |
| title_sort | persons never treated in mass drug administration for lymphatic filariasis identifying programmatic and research needs from a series of research review meetings 2020 2021 |
| work_keys_str_mv | AT bradyma personsnevertreatedinmassdrugadministrationforlymphaticfilariasisidentifyingprogrammaticandresearchneedsfromaseriesofresearchreviewmeetings20202021 AT toubalie personsnevertreatedinmassdrugadministrationforlymphaticfilariasisidentifyingprogrammaticandresearchneedsfromaseriesofresearchreviewmeetings20202021 AT bakerm personsnevertreatedinmassdrugadministrationforlymphaticfilariasisidentifyingprogrammaticandresearchneedsfromaseriesofresearchreviewmeetings20202021 AT longe personsnevertreatedinmassdrugadministrationforlymphaticfilariasisidentifyingprogrammaticandresearchneedsfromaseriesofresearchreviewmeetings20202021 AT worrellc personsnevertreatedinmassdrugadministrationforlymphaticfilariasisidentifyingprogrammaticandresearchneedsfromaseriesofresearchreviewmeetings20202021 AT ramaiahk personsnevertreatedinmassdrugadministrationforlymphaticfilariasisidentifyingprogrammaticandresearchneedsfromaseriesofresearchreviewmeetings20202021 AT gravesp personsnevertreatedinmassdrugadministrationforlymphaticfilariasisidentifyingprogrammaticandresearchneedsfromaseriesofresearchreviewmeetings20202021 AT hollingsworthtd personsnevertreatedinmassdrugadministrationforlymphaticfilariasisidentifyingprogrammaticandresearchneedsfromaseriesofresearchreviewmeetings20202021 AT kellyhopel personsnevertreatedinmassdrugadministrationforlymphaticfilariasisidentifyingprogrammaticandresearchneedsfromaseriesofresearchreviewmeetings20202021 AT stukeld personsnevertreatedinmassdrugadministrationforlymphaticfilariasisidentifyingprogrammaticandresearchneedsfromaseriesofresearchreviewmeetings20202021 AT tripathib personsnevertreatedinmassdrugadministrationforlymphaticfilariasisidentifyingprogrammaticandresearchneedsfromaseriesofresearchreviewmeetings20202021 AT meansar personsnevertreatedinmassdrugadministrationforlymphaticfilariasisidentifyingprogrammaticandresearchneedsfromaseriesofresearchreviewmeetings20202021 AT matendecherosh personsnevertreatedinmassdrugadministrationforlymphaticfilariasisidentifyingprogrammaticandresearchneedsfromaseriesofresearchreviewmeetings20202021 AT krentela personsnevertreatedinmassdrugadministrationforlymphaticfilariasisidentifyingprogrammaticandresearchneedsfromaseriesofresearchreviewmeetings20202021 |